Omicron, a new SARS-CoV-2 variant: assessing the impact on severity and vaccines efficacy.

Gaurav Joshi, Ramarao Poduri
Author Information
  1. Gaurav Joshi: School of Pharmacy, Graphic Era Hill University, Dehradun, India. ORCID
  2. Ramarao Poduri: GITAM Institute of Pharmacy, GITAM University, Visakhapatnam, India. ORCID

Abstract

The reply letter has been put forth in response to the comment made by Karthyayani Priya Satish entitled "India and the covid-19 Vaccine." The comment was made in context to our published work "Exploring the covid-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?" The reply letter is concerned with the newer variant of SARS-CoV-2, i.e., Omicron and its impact on severity and vaccine efficacy. Though the variant is mild, as per the reports, the cases are rising at an unprecedented rate that may create havoc on humankind considering shortages of RT-PCR testing and prevailing unequal vaccine distribution and vaccine hesitancy.

Keywords

References

  1. N Engl J Med. 2022 Feb 3;386(5):494-496 [PMID: 34965358]
  2. Int J Surg. 2022 Jan;97:106198 [PMID: 34958967]
  3. JAMA Netw Open. 2022 Sep 1;5(9):e2232760 [PMID: 36136332]
  4. Biomed Pharmacother. 2022 Feb;146:112527 [PMID: 34906769]
  5. Hum Vaccin Immunother. 2021 Dec 2;17(12):4714-4740 [PMID: 34856868]

MeSH Term

COVID-19
COVID-19 Vaccines
Humans
SARS-CoV-2
Vaccines

Chemicals

COVID-19 Vaccines
Vaccines

Word Cloud

Created with Highcharts 10.0.0vaccineSARS-CoV-2OmicronefficacyreplylettercommentmadevariantimpactseverityputforthresponseKarthyayaniPriyaSatishentitled"IndiaCOVID-19Vaccine"contextpublishedwork"Exploringcovid-19candidatesvariants:standgo?"concernednewerieThoughmildperreportscasesrisingunprecedentedratemaycreatehavochumankindconsideringshortagesRT-PCRtestingprevailingunequaldistributionhesitancynewvariant:assessingvaccinesCovid-19

Similar Articles

Cited By (9)